{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T06:11:24Z","timestamp":1698646284338},"reference-count":21,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,12,20]],"date-time":"2009-12-20T00:00:00Z","timestamp":1261267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> The objective of this study was to evaluate the efficacy and safety of pegylated interferon (PEG\u2010IFN) alpha\u20102a monotherapy in a cohort of Chinese haemophilic patients co\u2010infected with human immunodeficiency virus (HIV)\/hepatitis C virus (HCV) and undergoing highly active antiretroviral drugs therapy. Twenty\u2010two (<jats:italic>n<\/jats:italic>\u2003=\u200322) patients with CD4 lymphocyte counts over 200\u2003cells\u2003\u03bcL<jats:sup>\u22121<\/jats:sup> were treated with 180\u2003\u03bcg of PEG\u2010IFN alpha\u20102a subcutaneously once in a week for 48\u2003weeks. HCV load (HCV RNA), HIV load (HIV RNA) and CD4 lymphocyte counts were measured at baseline and 4, 12, 24, 48 and 72\u2003weeks after initiation of anti\u2010HCV therapy. Efficacy and safety were analysed according to baseline CD4 status (\u2265350\u2003cells\u2003\u03bcL<jats:sup>\u22121<\/jats:sup>). Significant HCV\u2010RNA decreases (&gt;1\u2003log<jats:sub>10<\/jats:sub>\u2003copies\u2003mL<jats:sup>\u22121<\/jats:sup>) were observed through week 72 after PEG\u2010INF alpha\u20102a monotherapy across both CD4 strata. CD4 status was not associated with treatment outcomes as evaluated using rapid viral response rate (<jats:italic>P<\/jats:italic>\u2003=\u20030.655), early viral response rate (<jats:italic>P<\/jats:italic>\u2003=\u20030.387), end\u2010of\u2010treatment viral response rate (<jats:italic>P<\/jats:italic>\u2003=\u20031.000) or sustained viral response rate (SVR, <jats:italic>P<\/jats:italic>\u2003=\u20030.674). A sustained virological response was achieved in nine patients (41%), five with genotype 2a (83%) and four with genotype 1b (25%, <jats:italic>P<\/jats:italic>\u2003=\u20030.023). SVR was HCV genotype dependent. Eleven patients required a dose reduction in PEG\u2010IFN alpha\u20102a. PEG\u2010IFN alpha\u20102a monotherapy could be considered as a safe and effective option for the treatment of HCV infection in HIV patients with haemophilia, particularly in resource\u2010limited settings. While higher CD4 lymphocyte counts resulted in greater HCV\u2010RNA reduction, HCV genotype was a predictor for sustained virological response.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2009.02170.x","type":"journal-article","created":{"date-parts":[[2009,12,21]],"date-time":"2009-12-21T02:47:44Z","timestamp":1261363664000},"page":"502-507","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of pegylated interferon alpha\u20102a therapy for chronic hepatitis C in HIV\u2010infected patients with haemophilia"],"prefix":"10.1111","volume":"16","author":[{"given":"R.\u2010F.","family":"ZHANG","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.\u2010Q.","family":"SUN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Q.","family":"HUANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.\u2010R.","family":"WANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.\u2010X.","family":"ZHANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.\u2010N.","family":"LIU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Q.","family":"MA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.\u2010Z.","family":"LU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,4,22]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/497148"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/318501"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2006.00791.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200204010-00009"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1351-8216.2003.00828.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.300.5.555"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31815ac47d"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318157b0da"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2007.00533.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.6.1231"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)70216-4"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.03.003"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.00222.x"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.07.013"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2000.00420.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200210173471623"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2007.11.005"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1089-3261(05)70244-0"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl497"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2009.02170.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2009.02170.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:56:01Z","timestamp":1698627361000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2009.02170.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,22]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1111\/j.1365-2516.2009.02170.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2009.02170.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,22]]}}}